Anti-Inflammatory Potential of the Selective Phosphodiesterase 4 Inhibitor N-(3,5-Dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl] -glyoxylic Acid Amide (AWD 12-281), in Human Cell Preparations

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 2, 2004, Pages 555-563

  Draheim, Regina ^a,b   Egerland, Ute ^a   Rundfeldt, Chris ^a  

^a Elbion AG   (Germany)

^b Elbion AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 NITROPHENYL) 3 (4 PYRIDYLMETHYL)PYRIDO[2,3 D]PYRIMIDIN 2,4(1H,3H) DIONE; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; AMIDE; AMINOPYRIDINE DERIVATIVE; ANTIINFLAMMATORY AGENT; BENZAMIDE DERIVATIVE; CILOMILAST; CONCANAVALIN A; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; CYTOKINE; DEXAMETHASONE; INDOLE DERIVATIVE; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHYTOHEMAGGLUTININ; PICLAMILAST; ROFLUMILAST; ROLIPRAM; RS 25344 000; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; DRUG BINDING SITE; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; INFLAMMATORY CELL; METABOLISM; MONONUCLEAR CELL; NORMAL HUMAN; NOSE POLYP; PATHOLOGY; POLYP; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMIDES; AMINOPYRIDINES; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOPROPANES; CYTOKINES; HUMANS; INDOLES; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; LEUKOCYTES, MONONUCLEAR; PHOSPHODIESTERASE INHIBITORS; POLYPS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1242268903     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.059097     Document Type: Article

References (40)

1. Alvarez R, Wilhelm R, Shelton ER, Daniels DV, Yang D, Kelly K, and Eglen RM (1994) Potent and selective inhibition of cyclic AMP specific phosphodiesterase (PDE IV) by structural analogs of nitraquazone. Can J Physiol Pharmacol 72 (Suppl 1):510.
2. Barnes PJ (2003) Therapy of chronic obstructive pulmonary disease. Pharmacol Ther 97:87-94.
3. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, and Torphy TJ (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284:420-426.
4. Braunstahl GJ, Fokkens WJ, Overbeck SE, KleinJan A, Hoogsteden HC, and Prins JB (2003) Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: a comparison between upper and lower airways. Clin Exp Allergy 33:579-587.
5. Burnouf C and Pruniaux MP (2002) Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 8:1255-1296.
6. 1-blockers. Int Arch Allergy Immunol 101:308-310.
7. Campbell AM, Chanez P, Marty-Ane C, Albat B, Bloom M, Michel B, Godard P, and Bousquet J (1993) Modulation of eicosanoid and histamine release from human dispersed lung cells by terfenadine. Allergy 48:125-129.
8. Cave A, Arlett P, and Lee E (1999) Inhaled and nasal corticosteroids: factors effecting the risk of systemic adverse effects. Pharmacol Ther 83:153-179.
9. Coffman RL, Ohara J, Bond MW, Caty J, Zlotnik A, and Paul WE (1986) B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol 136:4538-4541.
10. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, et al. (2001) Cilomilast, a selective phosphodiesterase 4 inhibition for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358:265-270.
11. Conti M and Yin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acids Res Mol Biol 63:1-38.
12. Endo H, Iwamoto I, Nakajima H, and Yoshida S (1993) In vitro interleukin 5 production of peripheral blood mononuclear cells is increased in patients with asthma. Int Arch Allergy Immunol 101:425-430.
13. Giembycz AM (2001) Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Exp Opin Investig Drugs 10:1361-1379.
14. Glavas NA, Ostenson C, Schaefer JB, Vasta V, and Beavo JA (2001) T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA 98:6319-6324.
15. Hatzelmann A and Schudt D (2001) Antiinflammatory and immunmodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279.
16. Heer S, Kuesters S, Marx D, and Szelenyi I (2000) Effect of phosphodiesterase inhibitors on cytokine release from human nasal polyp cells and human blood. Eur Resp J 16 (Suppl 31):162s
17. Heer S, Kuesters S, and Szelenyi I (1999) In vitro effect of the new selective phosphodiesterase4-inhibitor AWD 12-281 and of glucocorticoids on lipopolysaccharide (LPS)-induced TNFα-release in diluted and undiluted human blood of healthy volunteers. Naunyn-Schmiedeberg's Arch Pharmacol 359 (Supp 1):R85.
18. Hoefgen N, Egerland U, Poppe H, Marx D, Polymeropoulos E, Kronbach T, and Szelenyi S (1998) Structure based drug design of a new type of selective PDE4 inhibitors. 15th European Federation for Medicinal Chemistry International Symposium on Medicinal Chemistry (September 6-10, Edinburgh), Abstr. P98.
19. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, and Murphy KM (1992) Differential regulation of T helper phenotype development by interleukins 4 and 10 in an αβ T-cell-receptor transgenic system. Proc Natl Acad Sci USA 89:6065-6069.
20. Jimenez JL, Punzon C, Navarro J, Munoz-Fernandez MA, and Fresno M (2001) Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-κB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 299:753-759.
21. Konno S, Asano K, Okamoto K, and Adachi M (1994) Inhibition of cytokine production from human peripheral blood leukocytes by anti-allergic agents in vitro. Eur J Pharmacol 264:265-268.
22. Kuesters S, Tassabehji M, Rudert J, Wachs A, Szelenyi I, and Marx D (1999) The influence of phosphodiesterase inhibitors on cytokine release from human nasal polyp cells. Naunyn-Schmiedebergs Arch Pharmacol 359 (Suppl):R85.
23. Kuss H, Höfgen N, Egerland U, Heer S, Marx D, Szelenyi S, Schupke H, Gasparic A, Olbrich M, Hempel R, et al. (2002) AWD 12-281 antiasthmatic/antiinflammatory phosphodiesterase 4 inhibitor. Drugs Future 27:111-116.
24. Kuss H, Höfgen N, Johanssen S, Kronbach T, and Rundfeldt C (2003) In vivo efficacy in airway disease models of N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl] -glyoxylic acid amide (AWD12-281), a selective PDE4 inhibitor for inhaled administration. J Pharmacol Exp Ther 307:373-385.
25. Leckie JM and Walker C (2001) Interleukin-5 antagonism, in Progress in Respiratory Research, Drugs for Asthma, Allergy and COPD (Hansel TT and Barnes PJ eds) pp 265-268, Karger, Basel.
26. Leichtl S, Seyd J, Bredenbröker D, Rathgeb F, and Wurst W (2002) Efficacy of once daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165 (Suppl):A229.
27. Le Jeune IR, Shepherd M, Van Heeke G, Houslay MD, and Hall IP (2002) Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. J Biol Chem 277:35980-35989.
28. Leonard P and Sur S (2002) Asthma: future directions. Med Clin N Am 86:1131-1156.
29. Marx D, Tassabehji M, Heer S, Hüttenbrink K-B, and Szeleny I (2002) Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids. Pulm Pharmacol Ther 15:7-15.
30. Montana JG and Hazel JD (2002) Update on the therapeutic potential of PDE4 inhibitors. Exp Opin Investig Drugs 11:1-3.
31. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, and Dinarello CA (1990) Correlations and interactions in the production of interleukin 6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40-47.
32. Schmidt D, Szelenyi I, Poppe H, Magnussen H, and Rabe KF (1999) Effect of a novel PDE4 inhibitor AWD 12-281 on allergen-induced contractions in passively sensitized human airways. Am J Respir Crit Care Med 159 (Suppl):A854.
33. Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, and Giembycz MA (2003) Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 284:L279-L289.
34. Soderling SH and Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179.
35. Tattersfield AE, Knox AJ, Britton JR, and Hall IP (2002) Asthma. Lancet 360:1313-1322.
36. Torphy TJ (1998) Phosphodiesterase isoenzymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157:351-370.
37. Torphy TJ, Stadel JM, Burman M, Cieslinski IB, Mc Laughlin MM, White JF, and Livi GP (1992) Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 267:1798-1804.
38. Wenzel SE, Balzar S, Cundall M, and Chu HW (2003) Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation and wound repair. J Allergy Clin Immunol 111:1345-1352.
39. Wright LC, Seybold J, Robichaud A, Adcock IM, and Barnes PJ (1998) Phosphodiesterase expression in human epithelial cells. Am J Physiol Lung Cell Mol Physiol 275:L694-L700.
40. Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB (1995) Phenotype of cells expressing mRNA for Th2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 12:477-487.